Timothy R. Gershon

ResiPOx, a nanoparticle-delivered TLR7/8 agonist, reprograms tumor-associated myeloid cells to inhibit tumor growth in mouse models of medulloblastoma and diffuse midline glioma.

This study shows that PRC2 maintains neural identity in cerebellar progenitors and medulloblastoma, but its disruption does not block medulloblastoma progression.

This study shows that oligodendrocytes require MCL-1 to prevent apoptosis and white matter degeneration, suggesting MCL-1 deficiency contributes to leukodystrophy.

This paper develops a nanoparticle formulation of vismodegib that improves its efficacy for medulloblastoma treatment by enhancing CNS pharmacokinetics and reducing systemic toxicity.

The paper introduces MiniMUGA, a genotyping array for mouse genetic QC, showing it effectively discriminates strains, detects genetic constructs, and identifies sex chromosome abnormalities.